Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 10/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323646 | 0.75 | KDM4E (1.00) | KDM4EDNMT1SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL18323661 | 0.73 | POLB (0.47) | KDM4ESMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL18323644 | 0.73 | KDM4E (0.55) | KDM4EDNMT1SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL18323651 | 0.72 | KDM4E (0.64) | KDM4EDNMT1SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL18323636 | 0.72 | KDM4E (0.41) | KDM4ENOS3NOS2DNMT1 | |
| SCHEMBL18323647 | 0.69 | KDM4E (0.60) | KDM4EDNMT1SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL18323643 | 0.67 | KDM4E (0.56) | KDM4ESMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL18323638 | 0.66 | KDM4E (0.50) | KDM4EBRD4KMT2A | |
| SCHEMBL18323627 | 0.65 | KDM4E (0.41) | KDM4EDNMT1 | |
| SCHEMBL15907082 | 0.64 | KDM4E (0.37) | KDM4ENOS2DNMT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |